Goldman's 7 Favorite Biotech Ideas For 2016

Loading...
Loading...
Goldman Sachs highlighted seven favorite stocks in the biotech sector for the second half of the current year. These stocks offer upside potential between 13 percent and 175 percent.

Bluebird bio Inc BLUE provides the biggest upside potential, with 175 percent, whereas Agilent Technologies Inc A offered the least upside potential of 13 percent. Amgen, Inc. AMGN found a place on the America's Conviction Buy list.

Related Link: Exclusive: Why Martin Shkreli Feels He Has Been Vindicated

The following shares are Goldman's top picks in the sector with their attached price tags:

  • Agilent: Goldman Sachs kept a price objective of $53 based on conservative outlook along with enhanced dynamics on end market boosting EPS estimates.
  • AbbVie Inc ABBV: The brokerage is bullish on growth of Humira until the year 2019 in addition to the robust pipeline execution. Price tag at $78.
  • Amgen: The brokerage has $204 target price based on fresh product cycles and sees internal biosimilars replacing any loss of revenue due to competition.
  • Bluebird: Price tag of $135. The company is focused on rare diseases apart from oncology reaching key value-inflection points.
  • CIGNA Corporation CI: Target price is $160 on differentiated asset with exposure to fresh product cycles apart from consumer spending patterns.
  • Horizon Pharma PLC HZNP: Price objective is $27 based on stabilizing primary care business and PBM coverage expansion.
  • INC Research Holdings Inc INCR: Price tag is $82 on multiple catalysts like strong fundamentals, conservative consensus revenue estimates and valuation.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!
Loading...
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechLong IdeasHealth CarePrice TargetInitiationAnalyst RatingsTrading IdeasGeneralGoldman SachsHumira
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...